Qiagen Partners with Pathway Diagnostics, Sequenom on Dx, Biomarker Discovery | GenomeWeb
NEW YORK (GenomeWeb News) - Qiagen has agreed to a new marketing partnership with Pathway Diagnostics and has entered into a research agreement with Sequenom, the company said today.
 
Under the agreement with Malibu, Calif.-based Pathway, Qiagen said the companies will offer customers a bundled solution of Qiagen's assays and Pathway's clinical development and testing services, Qiagen said. Qiagen said it will use its sales force to "develop project opportunities" for the companies to address jointly.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.